MCID: INT068
MIFTS: 52

Intestinal Disease

Categories: Gastrointestinal diseases, Metabolic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Intestinal Disease

Summaries for Intestinal Disease

Disease Ontology: 11 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary: Intestinal Disease, also known as intestinal diseases, is related to crohn's disease and colonic disease, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cell differentiation - expanded index and DNA damage response (only ATM dependent). The drugs Prucalopride and Copper have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and bone marrow.

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure Congenital Intestinal Disease Due to an Enzymatic Defect
Intestinal Disease Due to Fat Malabsorption Intestinal Disease Due to Vitamin Absorption Anomaly
Rare Intestinal Disease

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 702)
# Related Disease Score Top Affiliating Genes
1 crohn's disease 32.4 MIR31 MIR21 MIR196A1 MIR142 ICOSLG H2AC18
2 colonic disease 32.4 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
3 gastrointestinal system disease 31.5 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
4 intestinal benign neoplasm 31.2 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
5 lymphoma, mucosa-associated lymphoid type 31.0 TP53 SDC1 MIR155 MIR142 ICOSLG CCR6
6 lymphoma, hodgkin, classic 31.0 TP53 MIR21 MIR155 ICOSLG H2AC18 CCR6
7 immune deficiency disease 31.0 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
8 marginal zone b-cell lymphoma 30.9 SDC1 MIR142 ICOSLG CCR6 BCL6
9 viral infectious disease 30.9 MIR21 MIR199A1 MIR155 ICOSLG H2AC18 CCR6
10 colonic benign neoplasm 30.8 TP53 MIR21 MIR199A1 MIR145 MIR143 H2AC18
11 cholangitis, primary sclerosing 30.8 TP53 MIR199A1 ICOSLG CCR6
12 lymphoma, non-hodgkin, familial 30.8 TP53 SDC1 MIR518A1 MIR31 MIR21 MIR199A1
13 deficiency anemia 30.8 TP53 MIR126 ICOSLG H2AC18 CCR6
14 diffuse large b-cell lymphoma 30.7 MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR145
15 sclerosing cholangitis 30.7 MIR199A1 ICOSLG CCR6
16 colorectal cancer 30.7 TP53 SDC1 MIR31 MIR21 MIR199A1 MIR196A1
17 head and neck cancer 30.6 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
18 pancreatic ductal adenocarcinoma 30.6 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
19 eye disease 30.6 TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR17
20 kidney cancer 30.6 TP53 MIR21 MIR199A1 MIR193A MIR17 MIR145
21 dermatitis, atopic 30.6 MIR21 MIR155 MIR142 ICOSLG CCR6
22 bone disease 30.6 MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR143
23 spinal cord disease 30.6 TP53 MIR199A1 MIR196A1 MIR155 MIR142 MIR126
24 leukemia, acute myeloid 30.5 TP53 SDC1 MIR31 MIR21 MIR199A1 MIR196A1
25 esophageal cancer 30.5 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
26 vascular disease 30.5 TP53 MIR21 MIR199A1 MIR145 MIR143 MIR126
27 leukemia, acute lymphoblastic 30.5 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
28 skin disease 30.5 TP53 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
29 myopathy 30.5 MIR21 MIR199A1 MIR196A1 MIR142 MIR126 ICOSLG
30 coccidiosis 30.5 ICOSLG H2AC18 CCR6
31 pulmonary disease, chronic obstructive 30.5 MIR21 MIR199A1 MIR17 MIR142 MIR126 ICOSLG
32 ovarian disease 30.5 TP53 MIR518A1 MIR21 MIR199A1 MIR17 MIR155
33 colorectal adenoma 30.5 TP53 MIR31 MIR21 MIR193A MIR17 MIR143
34 colorectal adenocarcinoma 30.5 TP53 MIR31 MIR193A MIR17 MIR145 MIR143
35 food allergy 30.5 ICOSLG CCR6 AOC1
36 gallbladder disease 30.5 TP53 MIR199A1 MIR196A1 MIR193A MIR17 MIR145
37 bladder cancer 30.5 TP53 MIR31 MIR21 MIR199A1 MIR17 MIR145
38 contact dermatitis 30.5 MIR21 MIR155 MIR142 ICOSLG CCR6
39 diabetes mellitus 30.4 TP53 MIR21 MIR17 MIR155 MIR145 MIR143
40 parasitic helminthiasis infectious disease 30.4 MIR21 ICOSLG H2AC18 CCR6
41 gastric cancer 30.4 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
42 non-alcoholic steatohepatitis 30.4 MIR21 MIR199A1 MIR142 CCR6
43 endometriosis 30.4 TP53 MIR199A1 MIR17 MIR145 MIR143 MIR142
44 alcohol use disorder 30.4 MIR199A1 MIR196A1 H2AC18 CCR6
45 allergic disease 30.4 MIR21 MIR155 ICOSLG H2AC18 CCR6 AOC1
46 anus cancer 30.4 TP53 H2AC18 CCR6
47 intestinal schistosomiasis 30.4 MIR199A1 ICOSLG CCR6
48 aortic aneurysm, familial abdominal, 1 30.4 MIR21 MIR199A1 MIR126 H2AC18 CCR6
49 burkitt lymphoma 30.4 TP53 MIR21 MIR155 MIR145 MIR143 BCL6
50 systemic scleroderma 30.4 MIR21 MIR142 ICOSLG H2AC18 CCR6

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation; diarrhea; signs and symptoms, digestive; anal or rectal pain

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8 3052762
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Tocopherol Approved, Investigational Phase 4 1406-66-2
4
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
5
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
6
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
7
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
13
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
14
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
17
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
18
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
19
Fidaxomicin Approved Phase 4 873857-62-6 151383
20
Simethicone Approved Phase 4 8050-81-5
21
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
25
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
26
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
27
Golimumab Approved Phase 4 476181-74-5
28
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
29
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
30
Glycopyrronium Approved, Investigational, Vet_approved Phase 4 596-51-0, 740028-90-4 3494
31
Ferric maltol Approved Phase 4 33725-54-1
32
Ferrous fumarate Approved Phase 4 141-01-5
33
Infliximab Approved Phase 4 170277-31-3
34
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
35
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
36
DL-alpha-Tocopherol Approved, Experimental, Investigational, Nutraceutical, Vet_approved Phase 4 59-02-9, 10191-41-0 2116 14985
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
38
Tocotrienol Investigational Phase 4 6829-55-6 9929901
39 Serotonin Receptor Agonists Phase 4
40 Copper Supplement Phase 4
41 Tocotrienols Phase 4
42 Tocopherols Phase 4
43 BB 1101 Phase 4
44 Antimitotic Agents Phase 4
45 Tubulin Modulators Phase 4
46 Citrate Phase 4
47 Piperazine citrate Phase 4
48 DMP 777 Phase 4 157341-41-8
49 Analgesics Phase 4
50 Anti-Inflammatory Agents, Non-Steroidal Phase 4

Interventional clinical trials:

(show top 50) (show all 860)
# Name Status NCT ID Phase Drugs
1 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
2 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
3 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
4 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
5 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Unknown status NCT03860012 Phase 4 Folic Acid
6 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Unknown status NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
7 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
8 Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
9 Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding Unknown status NCT01176864 Phase 4
10 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Completed NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
11 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
12 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
13 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole
14 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
15 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
16 Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Completed NCT03833999 Phase 4 Ondansetron 8mg;Lactulose;Placebo oral capsule
17 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
18 Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial Completed NCT04775732 Phase 4
19 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
20 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
21 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
22 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
23 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
24 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
25 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
26 A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy Completed NCT02334631 Phase 4 High Volume Simethicone;Standard Volume Simethicone
27 The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single-Blind, Randomized, Multi-center Study Completed NCT02486536 Phase 4 polyethylene glycol
28 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
29 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
30 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
31 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
32 Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). Recruiting NCT04626947 Phase 4
33 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
34 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
35 De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring Recruiting NCT04646187 Phase 4
36 Impact of Early Proactive Therapeutic Drug Monitoring on the Durability and Efficacy of Infliximab Therapy in Pediatric Inflammatory Bowel Disease: a Multicenter Open-label Randomized-control Trial Recruiting NCT05280405 Phase 4 Infliximab
37 Bilateral Mid-Abdominal Transverse Abdominis Plane and Rectus Sheath Blocks Comparing The Use of Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy Procedures. Recruiting NCT05224089 Phase 4 Liposomal Bupivicaine/Bupivacaine Admixture;Bupivacaine HCL
38 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn's Diseases Recruiting NCT01793831 Phase 4
39 An Assessor-blinded, Randomized, Controlled, Single Center, Parallel Design Trial With Patient Masking to Compare Early Postoperative Gastric Emptying Associated With Rocuronium Neuromuscular Reversal With Sugammadex Versus Neostigmine in Adults Undergoing Colon and Rectal Surgery Recruiting NCT04546672 Phase 4 Sugammadex;Neostigmine
40 Model-informed Infliximab Dose De-escalation Following Earlier Dose Escalation in Adult Patients With Inflammatory Bowel Diseases Recruiting NCT04982172 Phase 4 Infliximab
41 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Active, not recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution
42 Chronotherapy in Inflammatory Bowel Disease Active, not recruiting NCT04304950 Phase 4 Evening Group;Morning Group
43 Comparison for Efficacy and Safety of Bowel Preparation Between Oral Sulfate Table and 2L-polyethylene Glycol/Ascorbate in Elderly: Multicenter, Prospective, Investigator Single-blinded, Randomized Study Not yet recruiting NCT05249335 Phase 4 OST;2L-PEG/Asc
44 Predicting Response to Iron Supplementation in Patients With Inflammatory Bowel Disease During Induction Therapy Not yet recruiting NCT05456932 Phase 4 Intravenous iron;Ferric maltol;Ferrous fumarate
45 A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease Terminated NCT02566889 Phase 4 Infliximab
46 Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies Terminated NCT03866538 Phase 4 Withdrawal of Oral Budesonide
47 Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease Terminated NCT00205062 Phase 4
48 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
49 Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Unknown status NCT02044952 Phase 2, Phase 3 Mesalazine, Tripterygium glycosides
50 A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC Completed NCT03509220 Phase 3 PBK-1701TC;Standard oral preparation

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

Organs/tissues related to Intestinal Disease:

FMA: Intestine
MalaCards : Small Intestine, Bone Marrow, Colon, Spinal Cord, Bone, Liver, T Cells

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 2462)
# Title Authors PMID Year
1
The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis. 62
36461896 2022
2
The influence of nutrition on intestinal disease with emphasis on coccidiosis. 62
35791756 2022
3
Genetic selection of Eimeria parasites in the chicken for improvement of poultry health: implications for drug resistance and live vaccine development. 62
36102051 2022
4
Efficient oral delivery of water-soluble CT contrast agent using an W1/O/W2 alginate hydrogel matrix. 62
36201862 2022
5
Pathological mechanism of intestinal mucosal barrier injury of large intestine dampness-heat syndrome rats and the protective effect of Yujin powder. 62
36156378 2022
6
Per- and polyfluoroalkyl substances exposure and its influence on the intestinal barrier: An overview on the advances. 62
36055502 2022
7
The Impacts of Iron Overload and Ferroptosis on Intestinal Mucosal Homeostasis and Inflammation. 62
36430673 2022
8
Estrogen deficiency aggravates fluoride-induced small intestinal mucosa damage and junctional complexes proteins expression disorder in rats. 62
36252517 2022
9
Advancing intestinal organoid technology to decipher nano-intestine interactions and treat intestinal disease. 62
36465523 2022
10
Recent Research and Application Prospect of Functional Oligosaccharides on Intestinal Disease Treatment. 62
36364447 2022
11
Hydrogen Sulfide Metabolizing Enzymes in the Intestinal Mucosa in Pediatric and Adult Inflammatory Bowel Disease. 62
36421421 2022
12
Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription. 62
36279426 2022
13
A new surgical technique for short bowel syndrome. 62
36329426 2022
14
Apoptotic enteropathy, gluten intolerance, and IBD-like inflammation associated with lipotoxicity in DGAT1 deficiency-related diarrhea: a case report of a 17-year-old patient and literature review. 62
35763111 2022
15
Antioxidant activity and protective effect of wheat germ peptides in an in vitro celiac disease model via Keap1/Nrf2 signaling pathway. 62
36192986 2022
16
Pulmonary Crohn's Disease or Crohn's Disease with Lung Sarcoidosis? A Case Report and Literature Review. 62
36421591 2022
17
Celiac disease: New therapies on the horizon. 62
35921776 2022
18
Are Tp-e interval and QT dispersion values important in children with coeliac disease? 62
36278847 2022
19
An improved joint non-negative matrix factorization for identifying surgical treatment timing of neonatal necrotizing enterocolitis. 62
35575464 2022
20
Circ-ITCH overexpression promoted cell proliferation and migration in Hirschsprung disease through miR-146b-5p/RET axis. 62
35091706 2022
21
Challenges in the diagnosis of marginal zone lymphoma with symptoms of small intestinal disease: a case report and scoping review of the literature. 62
36388684 2022
22
Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB. 62
36043787 2022
23
Treatment of ulcerative colitis with Wu-Mei-Wan by inhibiting intestinal inflammatory response and repairing damaged intestinal mucosa. 62
35947900 2022
24
Compound Heterozygous Myosin 5B (Myo5b) Mutation with Early Onset Progressive Cholestasis and No Intestinal Failure. 62
34338607 2022
25
The transcription factor Cdx2 regulates inflammasome activity through expression of the NLRP3 suppressor TRIM31 to maintain intestinal homeostasis. 62
35985421 2022
26
Prevalence and Antimicrobial Resistance of Campylobacter jejuni and Campylobacter coli in Wild Birds from a Wildlife Rescue Centre. 62
36290276 2022
27
First DNA sequence proof for the occurrence of bovine adenovirus types 10 and 11 in continental Europe. 62
36315348 2022
28
Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. 62
36163498 2022
29
Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery. 62
36207740 2022
30
Cftr deletion in mouse epithelial and immune cells differentially influence the intestinal microbiota. 62
36289287 2022
31
Research progress on natural β-glucan in intestinal diseases. 62
36063888 2022
32
Decorated bacteria and the application in drug delivery. 62
35817214 2022
33
Intestinal cellular heterogeneity and disease development revealed by single-cell technology. 62
36045190 2022
34
Ji-Chuan decoction ameliorates slow transit constipation via regulation of intestinal glial cell apoptosis. 62
36160643 2022
35
[Efficacy and safety of adalimumab in patients with Crohn's disease]. 62
36008296 2022
36
PARASITOLOGIC AND PATHOLOGIC STUDY OF FREE-RANGING SOUTH AMERICAN RATTLESNAKES (CROTALUS DURISSUS TERRIFICUS) IN BRAZIL. 62
36214236 2022
37
The Use of Metabolomics as a Tool to Compare the Regulatory Mechanisms in the Cecum, Ileum, and Jejunum in Healthy Rabbits and with Diarrhea. 62
36139297 2022
38
Immunoproliferative Small Intestinal Disease Diagnosed by Double-balloon Endoscopy with Biopsy Sampling. 62
35135924 2022
39
Utility of Diagnostic Colonoscopy in Pediatric Intestinal Disease. 62
36233615 2022
40
Glucocorticoids-Induced Neuropsychiatric Disorders in Patients With Inflammatory Bowel Disease: A Systematic Review. 62
36225410 2022
41
Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease. 62
36004414 2022
42
[Nutritional problems in celiac patients. Difficulties in achieving an adequate nutritional status]. 62
36040008 2022
43
Severe Protein Loss in a 6-month-old Exclusively Breastfed Infant with Atopic Dermatitis. 62
36254543 2022
44
Comparative effects of fresh and sterile fecal microbiota transplantation in an experimental animal model of necrotizing enterocolitis. 62
35058059 2022
45
The "whole ingredients extract" of Astragali Radix improves the symptoms of dextran sulfate sodium-induced ulcerative colitis in mice through systemic immunomodulation. 62
36109750 2022
46
[Aseptic nasal septal abscess in patients with ulcerative colitis: two case reports. Case report]. 62
36286947 2022
47
In vitro effects of the 4-[(10H-phenothiazin-10-yl)methyl]-N-hydroxybenzamide on Giardia intestinalis trophozoites. 62
35483428 2022
48
Clinical outcomes of palliative self-expandable metal stent placement in right- and left-sided malignant colon obstruction: A Honam Association for the Study of Intestinal Disease (HASID) multicenter study. 62
36042619 2022
49
Trichopsychodermatology: trichotillomania and trichophagia leading to Rapunzel syndrome. 62
36090734 2022
50
PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition. 62
36016366 2022

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1A Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1A Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.45 MIR199A1 MIR17 MIR155 MIR145 MIR143
2 11.44 TP53 BCL6 APC
3 11.18 TP53 MIR21 MIR17 MIR145 MIR143
4 10.81 MIR21 MIR199A1 MIR155 MIR145 MIR126

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.6 MIR31 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
2 extracellular vesicle GO:1903561 9.26 MIR21 MIR193A MIR17 MIR126

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 TP53 MIR21 MIR199A1 MIR17 MIR155
2 positive regulation of protein kinase B signaling GO:0051897 9.81 MIR21 MIR199A1 MIR143 MIR126
3 negative regulation of angiogenesis GO:0016525 9.8 MIR21 MIR193A MIR145 MIR143
4 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR31 MIR143 MIR126
5 positive regulation of angiogenesis GO:0045766 9.72 MIR126 MIR143 MIR199A1 MIR21 MIR31
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR199A1 MIR196A1 MIR193A
7 miRNA-mediated gene silencing GO:0035195 9.64 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 MIR21 MIR199A1 MIR145
9 angiotensin-activated signaling pathway GO:0038166 9.58 MIR145 MIR143
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR199A1 MIR17
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
12 negative regulation of inflammatory response GO:0050728 9.55 MIR31 MIR199A1 MIR145 MIR142 MIR126
13 aorta smooth muscle tissue morphogenesis GO:0060414 9.54 MIR145 MIR143
14 positive regulation of metalloendopeptidase activity GO:1904685 9.52 MIR21 MIR17
15 regulation of phenotypic switching GO:1900239 9.43 MIR145 MIR143
16 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.4 MIR17 MIR143
17 positive regulation of cellular response to hypoxia GO:1900039 9.37 MIR21 MIR145
18 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIR31 MIR21 MIR17 MIR145 MIR126
19 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.73 TP53 MIR31 MIR21 MIR199A1 MIR193A MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.4 MIR518A1 MIR31 MIR21 MIR199A1 MIR196A1 MIR193A

Sources for Intestinal Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....